Business Context and Reporting Period
This Form 6-K filing by Bioblast Pharma Ltd. (now Enlivex Ltd.) covers the month of September 2016, with the report dated September 18, 2017. The filing documents the results of an Extraordinary General Meeting of Shareholders held on September 18, 2017.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions regarding share capital.
Material Changes
Shareholders approved a reverse split of the Company's share capital at a ratio of five to one. Under this action, every five ordinary shares with a par value of NIS 0.01 will be consolidated into one ordinary share with a par value of NIS 0.05.
Guidance, Outlook, and Risks
Management has not provided financial guidance or outlook in this specific filing. The Company stated it will advise shareholders regarding the effective date of the Reverse Split. No specific risks or contingencies were detailed beyond the execution of the capital reorganization.
Investor Verification Checklist
- Verify the official effective date of the 5-for-1 reverse split once announced by the Company.
- Confirm the updated share count and par value adjustments in subsequent filings.
- Review the Company's financial statements in other filings (e.g., Form 20-F) for actual financial performance data, as this 6-K contains none.